logo
Finwire

Finwire

Setback for Novartis and Novo Nordisk in heart disease trials

Swiss pharmaceutical giant Novartis and Danish company Novo Nordisk have failed to reduce the risk of major cardiovascular events in two large clinical trials. Reuters reports this, citing results presented at the American Heart Association’s congress in Chicago.

Novartis’s drug candidate pelacarsen lowered levels of the inherited risk factor Lp(a) by 78 percent, but did not reduce the risk of, among other things, heart attack, stroke or death.

The study included more than 8,300 patients who were followed for nearly five years. More patients discontinued treatment because of side effects than in the placebo group.

Novo Nordisk’s anti-inflammatory drug ziltivekimab also failed to reduce the risk of major cardiovascular events, despite reducing inflammation. The study included 6,300 patients.

The results raise questions about the treatment strategies, but researchers stress that other drugs and patient groups may still produce positive results.

Phase 3 results for competing treatments from Amgen and Eli Lilly are expected in 2028 and 2029, respectively.

Share this post

Verifierad av MonsterInsights